샘플 요청 목록

 카트 문의
시장보고서
상품코드
1792963

세계의 소아 경련 치료제 시장

Infantile Spasm Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 377 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

소아 경련 치료제 세계 시장은 2030년까지 38억 달러에 달할 전망

2024년에 32억 달러로 추정되는 소아 경련 치료제 세계 시장은 분석 기간인 2024-2030년에 CAGR 2.9%로 성장하여 2030년에는 38억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 항경련제는 CAGR 2.7%를 기록하며 분석 기간 종료시에는 23억 달러에 달할 것으로 예측됩니다. 코르티코스테로이드의 성장률은 분석 기간 동안 CAGR 3.5%로 추정됩니다.

미국 시장은 8억 7,880만 달러로 추정, 중국은 CAGR 5.4%로 성장 예측

미국의 소아 경련 치료제 시장은 2024년에 8억 7,880만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 7억 4,370만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 5.4%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.1%와 2.2%로 예측됩니다. 유럽에서는 독일이 CAGR 1.6%로 성장할 것으로 예측됩니다.

세계의 소아 경련 치료제 시장 - 주요 동향과 촉진요인 정리

소아 경련이 시급한 치료 과제로 떠오른 이유는 무엇일까?

임상적으로 웨스트 증후군으로도 알려진 소아 경련은 치명적인 발달적 영향, 복잡한 신경생리학, 그리고 진단적 경각심 향상으로 인한 인식의 증가로 인해 소아 신경학의 최전선에 서게 되었습니다. 이 질환은 일반적으로 생후 1년 이내에 발병하며, 양성 경련 반사, 위식도 역류 자세 또는 단순 근간 대성 발작으로 오인하기 쉬운 짧은 시간 동안 폭발적인 축삭 수축을 나타내며, 발달 정지 또는 퇴행이 부정할 수 없을 때까지 나타납니다. 신경생리학자들은 현재 부정맥이라고 불리는 명백히 혼란스러운 뇌파의 징후를 인식하고 있으며, 신생아 집중 치료 환경에서 비디오 뇌파 모니터링 장비의 보급으로 조기 발견이 가능해졌습니다. 역학적 데이터에 따르면 출생아 1만 명당 약 2-4명이 발생하지만, 주산기 저산소성 허혈성 장애, 결절성 경화증, 산전 감염 등의 발생률이 높은 지역에서는 유병률이 증폭됩니다. 경련이 치료되지 않거나 최적으로 관리되지 않으면 인지 장애, 난치성 간질, 자폐 스펙트럼 행동으로 빠르게 진행되기 때문에 신경 발달을 유지하기 위해서는 신속한 치료적 개입이 필수적입니다. 간병인 지원 단체와 소셜 미디어 커뮤니티는 갑작스러운 눈맞춤 상실, 발달 지연, 치명적인 뇌파 소견을 호소하는 부모들의 목소리를 증폭시키며 일차 진료에서 소아 간질 전문의로의 의뢰 시간을 단축할 것을 의료 시스템에 촉구하고 있습니다. 그 결과, 임상의들은 현재 증상 발현 후 수개월이 아닌 수일 내에 질병 조절 치료를 시작해야 하는 윤리적, 물류적 요구에 직면해 있으며, 치료 패러다임을 재구성하고 소아 경련 치료제를 공중보건의 우선순위로 끌어올리고 있습니다.

과학적 혁신은 기존 호르몬 요법을 뛰어넘는 치료 성과를 가져올 수 있을까?

현대의 소아 경련 관리는 부신피질자극호르몬과 경구용 코르티코스테로이드를 중심으로 한 기존의 프로토콜을 훨씬 뛰어넘어 진화하고 있습니다. 두 가지 모두 경련을 종식시킬 수 있지만 고혈압, 면역억제, 가역적 뇌위축의 위험을 수반합니다. 정밀약리학은 γ-아미노부티르산 트랜스아미나제의 선택적 비가역적 억제제인 비가바트린을 결절성 경화증에 동반된 경련에 대한 1차 선택약물로서, 그리고 은폐된 사례에서 중요한 2차 선택약물로서 도입하였습니다. 현재 진행 중인 임상 3상 시험에서는 비가바트린의 고함량 누적 투여 시 나타나는 유명한 합병증인 비가역적 시야 결손을 최소화하면서 발작 억제를 유지하는 차세대 GABA 작용제 유사 약물을 평가하고 있습니다. 또한, 시냅스 및 시냅스 외 GABA-A 수용체를 조절하는 합성 신경 스테로이드인 가낙솔론도 평가되고 있으며, 프레드니솔론과의 병용투여에서 유망한 비맹검 유효성을 보여주었습니다. 또한, 에베로리무스와 같은 mTOR 경로 억제제는 결절성 경화증과 관련된 간질 발병의 기저에 있는 업스트림 조절 장애를 다루기 위해 종양학에서 재사용되고 있습니다. 유전자 특이적 치료에 대한 관심이 높아지고 있으며, CDKL5 결손증과 STXBP1 뇌병증에 대한 항센스 올리고뉴클레오티드가 검토되고 있습니다. 신경 조절 전략도 발전하고 있습니다. 영아에 대한 반응성 신경 자극은 아직 실험적이지만, 시상 중부의 시상핵을 표적으로 하는 뇌심부 자극은 동정적 사용 프로그램에 들어갔습니다. 영양 요법도 엄격한 심사를 거쳤습니다. 중쇄중성지방을 정밀하게 조정한 개선된 케토제닉 프로토콜은 고전적 케토제닉 식단의 대사적 부담을 줄이면서 경련을 감소시키는 것으로 입증되었습니다. 이러한 과학적 진보를 종합하면, 경련의 종식뿐만 아니라 그 기저에 있는 신경 발달의 궤적을 변화시키는 것을 목표로 하는 다차원적인 치료법이 탄생하고 있으며, 소아 경련 치료의 정밀성과 개별화의 새로운 시대가 도래할 것임을 예고하고 있습니다.

규제, 경제, 간병인 요인이 치료법의 채택과 접근성에 어떤 영향을 미치는가?

소아 경련 치료제의 경우, 실험실에서의 획기적인 발견에서 병상에서의 영향에 이르기까지, 규제 프레임워크, 지불자의 결정, 그리고 간병인의 삶의 현실에 의해 강하게 매개됩니다. 미국, 유럽, 일본에서 소아경련치료제가 희귀질환치료제로 지정되면 시장 독점권, 세제혜택, 심사기간 단축 등의 혜택이 주어져 혁신적인 약물의 진입이 가속화되지만, 그 결과 출시가격이 비싸게 책정되는 경우가 많습니다. 비용-편익 분석에 따르면, 발작을 조기에 조절하면 집중적인 발달 치료와 특수 교육 서비스를 줄일 수 있어 장기적으로 비용을 절감할 수 있는 것으로 나타났습니다. 많은 저자원 환경에서 ACTH는 여전히 생물학적 활성을 변화시키는 복합제로만 구할 수 있는 반면, 비가바트린 정제는 인도적 조달 경로가 없으면 종종 품절되거나 구할 수 없는 경우가 많습니다. 원격 신경학 플랫폼은 지역 병원과 3차 간질 센터를 연결하여 뇌파를 신속하게 판독하고 치료 시작을 권장함으로써 지리적 격차를 해소하기 시작했지만, 광대역 보급률과 임상의의 대역폭은 여전히 제한 요인으로 작용하고 있습니다. 간병인은 복잡한 스테로이드 감량 스케줄, 세심한 혈압 모니터링, 월별 안과 검사 등을 수행하면서 치료 순응도에 큰 역할을 하고 있습니다. 다국어 교육 툴킷, 문자메시지 리마인더 시스템, 동료 멘토링 프로그램은 치료 시작 후 중요한 6개월간의 순응도 유지에 효과적임이 입증되었습니다. 윤리위원회와 환자 옹호 위원회는 발작 지표와 함께 신경발달 평가지표를 포함하도록 요구함으로써 시험 설계에 영향을 미치고, 발달의 질을 고려한 규제 당국의 승인을 보장하고 있습니다. 이러한 비임상적 힘을 총칭하여 시장 침투와 치료의 형평성을 형성하고, 획기적인 과학이 정책 혁신 및 간병인 참여와 결합되어야 집단 수준의 영향을 미칠 수 있다는 점을 강조하고 있습니다.

소아 경련 치료제 시장의 성장 가속화의 원동력은?

소아 경련 치료제 시장의 성장은 진단의 민감도 향상, 유전학적 지식의 확대, 선진적인 상환 정책, 관리 가능한 안전성 프로파일로 우수한 효능을 약속하는 표적 치료제의 탄탄한 파이프라인 등 여러 요인에 의해 주도되고 있습니다. 첫째, 신생아 보육원 및 응급실에서의 고해상도 비디오 뇌파 모니터링의 보급으로 경련을 조기에 발견할 수 있게 되어 치료 가능한 집단이 확대되고, 속효성 약물의 가치가 강조되고 있습니다. 둘째, 차세대 시퀀싱 패널을 통해 예후를 밝힐 뿐만 아니라 분자 수준에서 치료적 개입을 가능하게 하는 병원성 돌연변이가 발견되어 유전자 특이적 치료제 및 동반진단 약물에 대한 투자가 가속화되고 있습니다. 셋째, 희귀질환 치료제 우대 조치와 소아 우선 심사 바우처는 상업적 리스크를 낮추고, 생명공학 기업들이 미충족 수요가 높은 소수의 적응증을 추구하도록 장려하고 있습니다. 넷째, 전국 간질 등록을 통해 얻은 실제 데이터가 조기 개입을 통해 인지기능이 개선된다는 강력한 증거를 제공함에 따라 보험회사 및 국가 의료 서비스는 고가의 치료비를 환급하고, 재택 스테로이드 투여 프로그램에도 자금을 지원하고 있습니다. 다섯째, 제약사와 간질센터와의 전략적 제휴를 통해 적응증 시험 설계를 통해 임상 2상 시험의 효율성을 높이고, 엄격성을 유지하면서 개발 기간을 단축하고 있습니다. 여섯째, 간병인 지원 네트워크의 확산은 일반인들의 인지도를 높이고, 연구를 위한 자금 조달을 촉진하며, 의약품 수입과 컴패니언 유스 액세스를 촉진하는 정책 개혁을 촉진하고 있습니다. 일곱째, 발작을 감지하는 웨어러블 단말기와 AI를 활용한 투약 알고리즘을 통합한 새로운 디지털 치료제가 약물 치료를 보완하고 부수적인 수익원을 개척하며 시장 전체 생태계를 강화할 태세를 갖추고 있습니다. 이러한 상호 연계된 추진력으로 소아 경련 치료제는 틈새시장 관심사에서 소아 신경과학 혁신의 활기차고 급성장하는 분야로 변모하고 있으며, 전 세계 어린이들의 생존, 인지, 삶의 질을 의미 있게 개선할 수 있는 태세를 갖추고 있습니다.

부문

치료 클래스(항경련제, 코르티코스테로이드, 기타 약물 종류별), 약물 유형(비가바트린, 부신피질 자극 호르몬, 기타 약물 유형), 용법 용량(고형제, 액체제)

조사 대상 기업 사례

  • Amneal Pharmaceuticals
  • ANI Pharmaceuticals
  • Biocodex SA
  • Boehringer Ingelheim
  • Catalyst Pharmaceuticals
  • Cipla Limited
  • Currax Pharmaceuticals LLC
  • Dr. Reddy's Laboratories Ltd.
  • GW Pharmaceuticals(Jazz Pharma)
  • Hikma Pharmaceuticals Plc
  • Ionis Pharmaceuticals
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Marinus Pharmaceuticals
  • Medexus Pharmaceuticals Inc.
  • Mylan(Viatris Inc.)
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.25

Global Infantile Spasm Therapeutics Market to Reach US$3.8 Billion by 2030

The global market for Infantile Spasm Therapeutics estimated at US$3.2 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$878.8 Million While China is Forecast to Grow at 5.4% CAGR

The Infantile Spasm Therapeutics market in the U.S. is estimated at US$878.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$743.7 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Infantile Spasm Therapeutics Market - Key Trends & Drivers Summarized

Why Is Infantile Spasm Emerging as an Urgent Therapeutic Priority?

Infantile spasm, also known clinically as West syndrome, has moved to the forefront of pediatric neurology because of its devastating developmental consequences, its complex neurophysiology, and its increasing visibility through improved diagnostic vigilance. The disorder typically strikes within the first year of life, presenting with clusters of brief but explosive axial contractions that are easily mistaken for benign startle reflexes, gastroesophageal reflux posturing, or simple myoclonic jerks until developmental arrest or regression becomes undeniable. Neurophysiologists now recognize a distinctly chaotic electroencephalographic signature called hypsarrhythmia, and widespread deployment of video EEG monitoring units in neonatal intensive care settings is driving earlier detection. Epidemiological data suggest an incidence of roughly two to four cases per ten thousand live births, yet prevalence is amplified in regions with high rates of perinatal hypoxic-ischemic injury, tuberous sclerosis complex, or prenatal infections-all factors that remain stubbornly common in many low-- and middle-income countries. Untreated or suboptimally managed spasms progress rapidly to cognitive impairment, refractory epilepsy, and autism-spectrum behaviors, making prompt therapeutic intervention essential for neurodevelopmental preservation. Caregiver advocacy groups and social media communities have amplified the voices of parents who describe sudden loss of eye contact, developmental plateau, and catastrophic EEG findings, pressing health systems to shorten referral times from primary care to pediatric epilepsy specialists. Consequently, clinicians now face both ethical and logistical imperatives to initiate disease-modifying therapy within days rather than months of symptom onset, reshaping treatment paradigms and elevating infantile spasm therapeutics to a public health priority.

Can Scientific Innovation Transform Treatment Outcomes Beyond Traditional Hormonal Protocols?

Contemporary management of infantile spasm is evolving well beyond legacy protocols centered on adrenocorticotropic hormone and oral corticosteroids, both of which can terminate spasms but carry risks of hypertension, immunosuppression, and reversible brain atrophy. Precision pharmacology has introduced vigabatrin, a selective irreversible inhibitor of gamma-aminobutyric-acid transaminase, as the first-line option for spasms associated with tuberous sclerosis complex and as a key second-line therapy in cryptogenic cases. Ongoing phase III trials are evaluating next-generation GABA-ergic analogues that maintain seizure suppression while minimizing irreversible visual field defects, a notorious complication seen with high cumulative vigabatrin exposure. Investigators are also assessing ganaxolone, a synthetic neurosteroid modulating synaptic and extrasynaptic GABA-A receptors, which has shown promising open-label efficacy when combined with prednisolone. Elsewhere, mTOR pathway inhibitors such as everolimus are being repurposed from oncology to address the upstream dysregulation underlying tuberous sclerosis-related epileptogenesis, offering a disease-targeted alternative rather than purely symptomatic control. Interest in gene-specific therapies is mounting, with antisense oligonucleotides being explored for CDKL5 deficiency and STXBP1 encephalopathy, both high-risk genotypes for early infantile spasms. Neuromodulation strategies are advancing as well: responsive neurostimulation for infants remains experimental, but deep brain stimulation targeting the centromedian thalamic nucleus has entered compassionate-use programs. Nutritional therapies are also under rigorous scrutiny; modified ketogenic protocols with precisely titrated medium-chain triglycerides are demonstrating spasm reduction while mitigating the metabolic burden of classic ketogenic diets. Collectively, these scientific advances are creating a multidimensional therapeutic landscape aimed not only at terminating spasms but also at altering the underlying neurodevelopmental trajectory, heralding a new era of precision and personalization in infantile spasm care.

How Do Regulatory, Economic, and Caregiver Factors Influence Therapy Adoption and Accessibility?

The pathway from laboratory breakthrough to bedside impact in infantile spasm therapeutics is strongly mediated by regulatory frameworks, payer decisions, and the lived realities of caregivers. Designation of infantile spasm treatments as orphan drugs in the United States, Europe, and Japan confers market exclusivity, tax incentives, and abbreviated review timelines, accelerating entry of innovative agents yet often resulting in premium launch prices. Cost-utility analyses reveal that early seizure control yields long-term savings by reducing intensive developmental therapies and special-education services, prompting some national health authorities to reimburse expensive biologics when robust real-world evidence supports durable cognitive gains. Still, disparities persist: in many low-resource settings, availability of ACTH remains limited to compounded formulations with variable bioactivity, while vigabatrin tablets are frequently out of stock or unaffordable without humanitarian procurement channels. Tele-neurology platforms are beginning to bridge geographic gaps by connecting regional hospitals to tertiary epilepsy centers for rapid EEG interpretation and treatment initiation recommendations, although broadband penetration and clinician bandwidth remain limiting factors. Caregivers play an outsized role in treatment adherence, juggling complex steroid taper schedules, vigilant blood-pressure monitoring, and monthly ophthalmologic exams. Educational toolkits in multiple languages, text-message reminder systems, and peer-mentor programs have proven effective in sustaining adherence during the critical six-month consolidation window that follows therapy onset. Ethics committees and patient-advocacy councils influence trial design by demanding inclusion of neurodevelopmental endpoints alongside seizure metrics, ensuring that developmental quality-of-life considerations guide regulatory approvals. Collectively, these non-clinical forces shape market penetration and therapeutic equity, underscoring that breakthrough science must be paired with policy innovation and caregiver engagement to achieve population-level impact.

What Is Driving the Accelerated Growth of the Infantile Spasm Therapeutics Market?

The growth in the infantile spasm therapeutics market is driven by several factors rooted in heightened diagnostic acuity, expanding genetic insights, progressive reimbursement policies, and a robust pipeline of targeted therapies that promise superior efficacy with manageable safety profiles. First, widespread adoption of high-resolution video EEG monitoring in newborn nurseries and emergency departments is identifying spasms earlier, enlarging the treatable population and emphasizing the value of rapid-acting agents. Second, next-generation sequencing panels are unmasking pathogenic variants that not only clarify prognosis but also point toward molecularly tailored interventions, accelerating investment in gene-specific therapeutics and companion diagnostics. Third, orphan-drug incentives and pediatric priority review vouchers are lowering commercial risk, encouraging biotech firms to pursue small-population indications with high unmet need. Fourth, real-world data from national epilepsy registries are providing compelling evidence that early intervention improves cognitive trajectories, prompting insurers and national health services to reimburse premium therapies and even fund home-based steroid administration programs. Fifth, strategic collaborations between pharmaceutical companies and academic epilepsy centers are streamlining phase II proof-of-concept studies through adaptive trial designs, shortening development timelines without compromising rigor. Sixth, the proliferation of caregiver advocacy networks is boosting public awareness, driving fundraising for research, and catalyzing policy reforms that facilitate medication importation and compassionate-use access. Seventh, emerging digital therapeutics that integrate seizure-detection wearables and AI-driven dosing algorithms are poised to complement pharmacologic regimens, opening ancillary revenue streams and reinforcing the overall market ecosystem. These interlocking drivers are collectively transforming infantile spasm therapeutics from a niche subspecialty concern into a vibrant, fast-growing domain of pediatric neuroscience innovation poised to deliver meaningful improvements in survival, cognition, and quality of life for affected infants worldwide.

SCOPE OF STUDY:

The report analyzes the Infantile Spasm Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutic Class (Anticonvulsants, Corticosteroids, Other Therapeutic Classes); Drug Type (Vigabatrin, Adrenocorticotropic Hormone, Other Drug Types); Dosage (Solid Dosage, Liquid Dosage)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Amneal Pharmaceuticals
  • ANI Pharmaceuticals
  • Biocodex SA
  • Boehringer Ingelheim
  • Catalyst Pharmaceuticals
  • Cipla Limited
  • Currax Pharmaceuticals LLC
  • Dr. Reddy's Laboratories Ltd.
  • GW Pharmaceuticals (Jazz Pharma)
  • Hikma Pharmaceuticals Plc
  • Ionis Pharmaceuticals
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Marinus Pharmaceuticals
  • Medexus Pharmaceuticals Inc.
  • Mylan (Viatris Inc.)
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Infantile Spasm Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis Rates and Early Intervention Efforts Throw the Spotlight on Infantile Spasm Therapeutics as a Critical Segment in Pediatric Neurology
    • Increasing Awareness Among Pediatricians and Neurologists Propels Demand for Timely and Evidence-Based Treatment Approaches
    • Here's the Story: Clinical Guidelines Emphasizing Early Treatment Strengthen the Business Case for First-Line Therapeutics
    • Advances in Neuroimaging and EEG Technologies Drive Earlier and More Accurate Identification of Infantile Spasms
    • Growing Pipeline of ACTH Analogs, Steroids, and Antiepileptic Drugs Supports Innovation in Drug Formulations and Dosing Regimens
    • Here's How Research in Genetic and Metabolic Causes of Infantile Spasms Is Opening Doors to Targeted Therapies
    • Rising Focus on Neurodevelopmental Outcomes Fuels Demand for Fast-Acting and Tolerable Therapeutic Options
    • Global Expansion of Pediatric Specialty Clinics Enhances Access to Infantile Spasm Treatment in Urban and Semi-Urban Areas
    • Growth in Specialty Pharmaceuticals and Orphan Drug Designation Accelerates R&D and Market Entry of Novel Therapeutics
    • Emergence of Precision Medicine and Genetic Screening Fuels Long-Term Potential for Personalized Infantile Spasm Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Infantile Spasm Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Infantile Spasm Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Vigabatrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Vigabatrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Vigabatrin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Adrenocorticotropic Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Adrenocorticotropic Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Adrenocorticotropic Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Solid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Solid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Solid Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Liquid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Liquid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Liquid Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • JAPAN
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • CHINA
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • EUROPE
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Infantile Spasm Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • FRANCE
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: France 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • GERMANY
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • INDIA
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: India 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Infantile Spasm Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Infantile Spasm Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030
  • AFRICA
    • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Infantile Spasm Therapeutics by Therapeutic Class - Anticonvulsants, Corticosteroids and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Infantile Spasm Therapeutics by Therapeutic Class - Percentage Breakdown of Value Sales for Anticonvulsants, Corticosteroids and Other Therapeutic Classes for the Years 2014, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Infantile Spasm Therapeutics by Drug Type - Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Infantile Spasm Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Vigabatrin, Adrenocorticotropic Hormone and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Infantile Spasm Therapeutics by Dosage - Solid Dosage and Liquid Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Infantile Spasm Therapeutics by Dosage - Percentage Breakdown of Value Sales for Solid Dosage and Liquid Dosage for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제